Sue Goldie

Q: What Schools Are Affiliated With Sue Goldie

Sue Goldie is affiliated with the following schools: Albany Medical College, Union College, New York, Harvard University

Sue Goldie's AcademicInfluence.com Rankings

Sue Goldie

Political Science

#2058

World Rank

#2425

Historical Rank

#973

USA Rank

Public Policy

#313

World Rank

#324

Historical Rank

#162

USA Rank

political-science Degrees

Sue Goldie

Philosophy

#10101

World Rank

#13815

Historical Rank

#1837

USA Rank

Logic

#7299

World Rank

#9016

Historical Rank

#1085

USA Rank

philosophy Degrees

Download Badge

Political Science
Philosophy

Sue Goldie's Degrees

Doctorate Medicine Harvard University

Why Is Sue Goldie Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Sue J. Goldie is the Roger Irving Lee Professor of Public Health, the Director of the Center for Health Decision Science , Director of the Global Health Education and Learning Incubator at Harvard University, and founding Faculty Director of the Harvard Global Health Institute . Goldie has a secondary appointment as Professor of Global Health and Social Medicine . Her professional agenda includes improving women's health in all parts of the world, using evidence-based policy to reduce global health inequities, building bridges between disciplines to tackle critical public health challenges, and fostering innovation in education.

(See a Problem?)

Sue Goldie's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Global health 2035: a world converging within a generation (2013) (1091)
Cost-effectiveness of cervical-cancer screening in five developing countries. (2005) (673)
Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. (2004) (577)
Interim Guidance for the Use of Human Papillomavirus DNA Testing as an Adjunct to Cervical Cytology for Screening (2004) (519)
The cost effectiveness of combination antiretroviral therapy for HIV disease. (2001) (499)
Guidelines for preventing opportunistic infections among HIV-infected persons - 2002 (2002) (474)
The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. (1999) (424)
American Cancer Society Guideline for Human Papillomavirus (HPV) Vaccine Use to Prevent Cervical Cancer and Its Precursors (2007) (408)
Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. (2001) (396)
Human papillomavirus and HPV vaccines: a review. (2007) (366)
Health and economic implications of HPV vaccination in the United States. (2008) (356)
Introducing HPV vaccine in developing countries--key challenges and issues. (2007) (323)
Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. (2002) (279)
Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire. (2006) (272)
Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. (2003) (269)
Use of Genotypic Resistance Testing To Guide HIV Therapy: Clinical Impact and Cost-Effectiveness (2001) (251)
Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States (2009) (237)
Cost-Effectiveness of Human Papillomavirus DNA Testing for Cervical Cancer Screening in Women Aged 30 Years or More (2004) (229)
A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV‐16/18 vaccine (2003) (229)
Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. (2008) (226)
Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. (2005) (212)
Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. (2008) (207)
Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes. (2006) (201)
Cost-effectiveness of screening for anal squamous intraepithelial lesions and anal cancer in human immunodeficiency virus-negative homosexual and bisexual men. (2000) (197)
Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. (2008) (190)
Clinical effectiveness and cost-effectiveness of 2 management strategies for infected total hip arthroplasty in the elderly. (2001) (178)
Fungal peritonitis in a large chronic peritoneal dialysis population: a report of 55 episodes. (1996) (174)
Cost-effectiveness of HPV 16, 18 vaccination in Brazil. (2007) (163)
The economic burden of noncervical human papillomavirus disease in the United States. (2008) (157)
Multiparameter calibration of a natural history model of cervical cancer. (2007) (157)
Screening for Chlamydia trachomatis in Women 15 to 29 Years of Age: A Cost-Effectiveness Analysis (2004) (157)
The effectiveness of yoga in modifying risk factors for cardiovascular disease and metabolic syndrome: A systematic review and meta-analysis of randomized controlled trials (2016) (150)
HPV Communication: Review of Existing Research and Recommendations for Patient Education (2004) (150)
Modeling cervical cancer prevention in developed countries. (2008) (142)
Empirically calibrated model of hepatitis C virus infection in the United States. (2002) (132)
Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India (2008) (128)
Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy. (2005) (127)
Alternative Strategies to Reduce Maternal Mortality in India: A Cost-Effectiveness Analysis (2010) (126)
Women's desired information about human papillomavirus (2004) (125)
Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. (2003) (117)
The estimated mortality impact of vaccinations forecast to be administered during 2011-2020 in 73 countries supported by the GAVI Alliance. (2013) (117)
Cost-utility analyses of clinical preventive services: published ratios, 1976-1997. (2000) (115)
The Costs, Clinical Benefits, and Cost-Effectiveness of Screening for Cervical Cancer in HIV-Infected Women (1999) (115)
Comparison of Health State Utilities Using Community and Patient Preference Weights Derived from a Survey of Patients with HIV/AIDS (2002) (112)
Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination (2007) (110)
A Refined Estimate of the Average Lifetime Cost of Pelvic Inflammatory Disease (2003) (107)
The cost-effectiveness of air bags by seating position. (1997) (106)
When does quality-adjusting life-years matter in cost-effectiveness analysis? (2004) (105)
Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS). (2006) (101)
Chapter 18: Public health policy for cervical cancer prevention: the role of decision science, economic evaluation, and mathematical modeling. (2006) (97)
Cost-effectiveness analyses of vaccination programmes : a focused review of modelling approaches. (2008) (96)
News media coverage of human papillomavirus (2004) (95)
Estimated economic impact of vaccinations in 73 low- and middle-income countries, 2001–2020 (2017) (94)
Chapter 19: Cost-effectiveness of cervical cancer screening. (2006) (92)
[Global health 2035: a world converging within a generation]. (2015) (89)
Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d’Ivoire: a trial-based analysis (2005) (89)
Exploring the cost‐effectiveness of Helicobacter pylori screening to prevent gastric cancer in China in anticipation of clinical trial results (2009) (87)
Health and economic impact of HPV 16/18 vaccination and cervical cancer screening in Eastern Africa (2012) (86)
Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness analysis (2015) (82)
Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. (2008) (81)
Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications (2008) (79)
A Model-Based Estimate of Cumulative Excess Mortality in Survivors of Childhood Cancer (2010) (76)
Cost-Effectiveness Analyses of Vaccination Programmes (2012) (74)
The German cervical cancer screening model: development and validation of a decision-analytic model for cervical cancer screening in Germany. (2006) (71)
Economic evaluation of pneumococcal conjugate vaccination in The Gambia (2010) (70)
Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus. (2001) (69)
COST-EFFECTIVENESS IMPLICATIONS OF THE TIMING OF ANTIRETROVIRAL THERAPY IN HIV-INFECTED ADULTS (2002) (69)
Cost-Effectiveness of Human Papillomavirus Vaccination and Cervical Cancer Screening in Women Older Than 30 Years in the United States (2009) (69)
Incidence of primary opportunistic infections in two human immunodeficiency virus-infected French clinical cohorts. (2001) (67)
Cost-effectiveness of Rotavirus vaccination in Vietnam (2009) (67)
Mathematical models of cervical cancer prevention in Latin America and the Caribbean. (2008) (67)
Cost‐effectiveness analysis of cervical cancer prevention based on a rapid human papillomavirus screening test in a high‐risk region of China (2010) (67)
Reducing Risks to Children in Vehicles With Passenger Airbags (1998) (66)
Alma-Ata at 40 years: reflections from the Lancet Commission on Investing in Health (2018) (66)
Clinical consequences and cost of limiting use of vancomycin for perioperative prophylaxis: example of coronary artery bypass surgery. (2001) (65)
Health Service Interventions for Cancer Control in Developing Countries (2006) (65)
Cost-Effectiveness of Rapid Point-of-Care Prenatal Syphilis Screening in Sub-Saharan Africa (2008) (64)
Cost-effectiveness of earlier initiation of antiretroviral therapy for uninsured HIV-infected adults. (2001) (64)
Exploring the cost-effectiveness of HPV vaccination in Vietnam: insights for evidence-based cervical cancer prevention policy. (2008) (64)
Recommendations for cervical cancer prevention in Asia Pacific. (2008) (63)
Health and economic impact of rotavirus vaccination in GAVI-eligible countries (2010) (63)
Recommendations for cervical cancer prevention in Latin America and the Caribbean. (2008) (62)
Economic evaluation of hepatitis B vaccination in low-income countries: using cost-effectiveness affordability curves. (2007) (62)
Projection of the Future Dimensions and Costs of the Genital Herpes Simplex Type 2 Epidemic in the United States (2002) (62)
Cost‐effectiveness of treatment and endoscopic surveillance of precancerous lesions to prevent gastric cancer (2010) (62)
Mathematical models of cervical cancer prevention in the Asia Pacific region. (2008) (61)
Trade-offs in cervical cancer prevention: balancing benefits and risks. (2008) (61)
1999 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus (1999) (59)
Cytomegalovirus as a primary pulmonary pathogen in AIDS. (1997) (59)
Economic Evaluation of Weight Loss Interventions in Overweight and Obese Women (2006) (58)
Laboratory Monitoring to Guide Switching Antiretroviral Therapy in Resource-Limited Settings: Clinical Benefits and Cost-Effectiveness (2010) (56)
Cost-Effectiveness of an Intervention to Improve Adherence to Antiretroviral Therapy in HIV-Infected Patients (2006) (56)
TIME COSTS ASSOCIATED WITH CERVICAL CANCER SCREENING (2001) (56)
Treatment for hepatitis C virus in human immunodeficiency virus-infected patients: clinical benefits and cost-effectiveness. (2002) (53)
Assessing the Sensitivity of Decision-Analytic Results to Unobserved Markers of Risk: Defining the Effects of Heterogeneity Bias (2002) (53)
Assessing Preferences for Prevention versus Treatment Using Willingness to Pay (2002) (53)
Lifetime Cost of HIV Care in France during the Era of Highly Active Antiretroviral Therapy (2001) (53)
The Costs, Benefits, and Cost-Effectiveness of Interventions to Reduce Maternal Morbidity and Mortality in Mexico (2007) (53)
Estimating the cost of cervical cancer screening in five developing countries (2006) (51)
The Cost Effectiveness of Gonorrhea Screening in Urban Emergency Departments (2005) (47)
Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines. (2002) (46)
Chapter 15: Public health policy and cost-effectiveness analysis. (2003) (45)
Comparative Effectiveness of Personalized Lifestyle Management Strategies for Cardiovascular Disease Risk Reduction (2016) (45)
National and sub-national analysis of the health benefits and cost-effectiveness of strategies to reduce maternal mortality in Afghanistan. (2013) (45)
Cost-effectiveness of human papillomavirus vaccination and screening in Spain. (2010) (44)
The costs of reducing loss to follow-up in South African cervical cancer screening (2005) (44)
Clinical Benefits, Costs, and Cost-Effectiveness of Neonatal Intensive Care in Mexico (2010) (44)
Cost-Effectiveness of Alternative Blood-Screening Strategies for West Nile Virus in the United States (2006) (44)
Effects of Helicobacter pylori infection and smoking on gastric cancer incidence in China: a population-level analysis of trends and projections (2009) (42)
Cost-effectiveness of organized versus opportunistic cervical cytology screening in Hong Kong. (2004) (42)
Cost-Effectiveness of Human Papillomavirus Vaccination and Cervical Cancer Screening in Women Older Than 30 Years in the United States (2009) (42)
TREATMENT FOR PRIMARY HIV INFECTION: PROJECTING OUTCOMES OF IMMEDIATE, INTERRUPTED, OR DELAYED THERAPY (2002) (39)
The relationship of preventable opportunistic infections, HIV-1 RNA, and CD4 Cell counts to chronic mortality. (2002) (38)
The cost-effectiveness of elective Cesarean delivery for HIV-infected women with detectable HIV RNA during pregnancy (2000) (38)
Cost-Effectiveness of Enfuvirtide in Treatment-Experienced Patients With Advanced HIV Disease (2005) (37)
Packaging Health Services When Resources Are Limited: The Example of a Cervical Cancer Screening Visit (2006) (36)
Assessing health and economic outcomes of interventions to reduce pregnancy-related mortality in Nigeria (2012) (35)
The Impact of Natural History Parameters on the Cost-Effectiveness of Chlamydia trachomatis Screening Strategies (2006) (33)
Health economics and cervical cancer prevention: a global perspective. (2002) (33)
Keeping the noise down: common random numbers for disease simulation modeling (2008) (33)
Preevaluation of clinical trial data: the case of preemptive cytomegalovirus therapy in patients with human immunodeficiency virus. (2001) (32)
State AIDS Drug Assistance Programs: Equity and Efficiency in an Era of Rapidly Changing Treatment Standards (2002) (32)
CHAPTER 10 A public health approach to cervical cancer control: Considerations of screening and vaccination strategies (2006) (31)
The Cost-Effectiveness of Directly Observed Highly-Active Antiretroviral Therapy in the Third Trimester in HIV-Infected Pregnant Women (2010) (30)
Prevention of human immunodeficiency virus-related opportunistic infections in France: a cost-effectiveness analysis. (2003) (30)
Use of visual screening methods for cervical cancer screening. (2002) (30)
Taking account of future technology in cost effectiveness analysis (2004) (30)
Human papillomavirus vaccine policy and delivery in Latin America and the Caribbean. (2008) (30)
Rationing Decisions and Individual Responsibility for Illness: Are all Lives Equal? (2003) (29)
Empirically evaluating decision-analytic models. (2010) (29)
A public health approach to cervical cancer control: considerations of screening and vaccination strategies. (2006) (29)
Public health policy and cost-effectiveness analysis (2003) (28)
HIV drug resistance surveillance for prioritizing treatment in resource-limited settings (2007) (28)
Cost-effectiveness analysis of unsafe abortion and alternative first-trimester pregnancy termination strategies in Nigeria and Ghana. (2010) (28)
Contribution of H. pylori and Smoking Trends to US Incidence of Intestinal-Type Noncardia Gastric Adenocarcinoma: A Microsimulation Model (2013) (28)
Program Spending to Increase Adherence: South African Cervical Cancer Screening (2009) (28)
Cost-effectiveness of treatment for hepatitis C in an urban cohort co-infected with HIV. (2007) (27)
A Monte Carlo Simulation of Advanced HIV Disease (1998) (26)
The cost-effectiveness of elective Cesarean delivery to prevent hepatitis C transmission in HIV-coinfected women (2004) (25)
Continuous Peritoneal Dialysis-Associated Peritonitis of Nosocomial Origin (1996) (25)
Comparative evaluation of the potential impact of rotavirus versus hpv vaccination in GAVI-eligible countries: A preliminary analysis focused on the relative disease burden (2011) (24)
Optimal Frequency of Cd4 Cell Count and HIV Rna Monitoring Prior to Initiation of Antiretroviral Therapy in HIV-Infected Patients (2005) (23)
A therapeutic HIV vaccine: how good is good enough? (2004) (23)
Development of an Empirically Calibrated Model of Gastric Cancer in Two High-Risk Countries (2008) (23)
Estimating the costs and benefits of screening monogamous, heterosexual couples for unrecognised infection with herpes simplex virus type 2 (2003) (22)
Cost-effectiveness of cervical cancer screening (2006) (21)
Health and economic impact of human papillomavirus 16 and 18 vaccination of preadolescent girls and cervical cancer screening of adult women in Peru. (2012) (20)
Cost-effectiveness analysis of treatment strategies for Stage I and II endometrial cancer. (2007) (20)
A Potential Error in Evaluating Cancer Screening: A Comparison of 2 Approaches for Modeling Underlying Disease Progression (2003) (20)
Model-based analyses to compare health and economic outcomes of cancer control: inclusion of disparities. (2011) (19)
A Health Services Research Agenda for Cellular, Molecular and Genomic Technologies in Cancer Care (2009) (19)
Cost-effectiveness analysis: an introductory guide for clinicians. (1999) (18)
Impact of opportunistic diseases on chronic mortality in HIV-infected adults in Côte d'Ivoire. (2006) (18)
Does Cost-Effectiveness Analysis Make a Difference? (2001) (18)
Potential impact of reactive vaccination in controlling cholera outbreaks: an exploratory analysis using a Zimbabwean experience. (2011) (17)
Improving child health through healthy timing and spacing of pregnancies in rural Ethiopia. (2016) (17)
Predictors of hazardous child seating behavior in fatal motor vehicle crashes: 1990 to 1998. (2001) (15)
Assessing the Performance of a Computer-Based Policy Model of HIV and AIDS (2010) (13)
Genomics in Medicine and Public Health: Role of Cost-effectiveness Analysis (2001) (12)
Effects of Direct-to-Consumer Advertising and Clinical Guidelines on Appropriate Use of Human Papillomavirus DNA Tests (2011) (11)
Exploring Model Uncertainty in Economic Evaluation of Health Interventions: The Example of Rotavirus Vaccination in Vietnam (2010) (11)
Blood screening for west nile virus: the cost-effectiveness of a real-time, trigger-based strategy. (2006) (9)
Cost-utility analyses of clinical preventive services11The full text of this article is available via AJPM Online at http://www.elsevier.com/locate/ajpmonline. (2000) (7)
Diagnostic tests in HIV management: a review of clinical and laboratory strategies to monitor HIV-infected individuals in developing countries. (2006) (7)
Screening for cervical cancer. (2000) (6)
PIN37 A COMPREHENSIVE NATURAL HISTORY MODEL OF HUMAN PAPILLOMAVIRUS (HPV) INFECTION AND CERVICAL CANCER: POTENTIAL IMPACT OF AN HPV 16/18 VACCINE (2002) (6)
Budget Impact of Medicaid Section 1115 Demonstrations for Early HIV Treatment (2005) (5)
Effects of cardioactive medications on retrograde conduction: Continuing relevance for current devices (2006) (5)
Patient- and population-level health consequences of discontinuing antiretroviral therapy in settings with inadequate HIV treatment availability (2012) (4)
ICO Monograph Series on HPV and Cervical Cancer: Latin America and the Caribbean Regional Report Mathematical Models of Cervical Cancer Prevention in Latin America and the Caribbean (2008) (4)
Global Health 2035 (2017) (4)
Are European-specific guidelines needed for prevention of opportunistic infections in HIV-1? (1999) (3)
PCN2 COST-EFFECTIVENESS OF NEW CERVICAL CANCER SCREENING TECHNOLOGIES:A GERMAN HEALTH TECHNOLOGY ASSESSMENT AND DECISION-ANALYSIS (2002) (3)
msJAMA. Genomics in medicine and public health: role of cost-effectiveness analysis. (2001) (2)
Finding consensus on cervical cancer prevention. (2012) (2)
Book Review Calculated Risks: How to Know When Numbers Deceive You By Gerd Gigerenzer. 310 pp., illustrated. New York, Simon & Schuster, 2002. $25. 0-7432-0556-1 (2003) (1)
Simulation-based estimates and projections of global, regional and country-level maternal mortality by cause, 1990-2050. (2023) (1)
Human Papillomavirus and HPV Vaccines: A review/Virus Du Papillome Humain et Vaccins Anti-VPH: bilan/Papilomavirus Humanos Y Vacunas Anti-PVH: Revision (2007) (1)
Prevent Cervical Cancer and Its Precursors American Cancer Society Guideline for Human Papillomavirus (HPV) Vaccine Use to (2007) (1)
Comment on: Cost-Effectiveness of Cervical Cancer Screening With Human Papillomavirus DNA Testing and HPV-16,18 Vaccination. Authors' reply (2008) (1)
Safety and Efficacy of Biodegradable Nasopore Nasal Packing In Functional Endoscopic Sinus Surgery (2014) (1)
Anal cancer in HIV infection: to screen or not to screen? (2004) (1)
Diagnosis and treatment of Pneumocystis carinii pneumonia : Economic issues and cost-effectiveness (1999) (0)
Afghanistan Progress: A Matter of Perspective (2017) (0)
Communications to the EditorCytomegalovirus as a Pulmonary Pathogen (1997) (0)
PCN22 A SYSTEMATIC EVALUATION OF THE IMPACT OF THE SCREENING INTERVAL ON EFFECTIVENESS AND COST-EFFECTIVENESS OF DIFFERENT CERVICAL CANCER SCREENING TECHNIQUES (2004) (0)
Cost-effectiveness analysis of strategies for the surgical management of grade 1 endometrial adenocarcinoma. (2007) (0)
PCN38 THE IMPACT OF SCREENING ADHERENCE ON MEDICAL EFFECTIVENESS AND COST-EFFECTIVENESS OF CERVICAL CANCER SCREENING IN GERMANY—A DECISION ANALYSIS (2004) (0)
PCN3 POTENTIAL IMPACT OF WANING OF VACCINE-INDUCED IMMUNITY AGAINST HUMAN PAPILLOMAVIRUS 16/18 (2004) (0)
The Relationship of Preventable Opportunistic Infections, HIV‐1 RNA, and CD4 Cell Counts to Chronic Mortality (2002) (0)
Human Papillomavirus and Oropharyngeal Cancer (2007) (0)
Relative Cost-Effectiveness of Different Tests for Chlamydia trachomatis (2005) (0)
Strengthening Afghanistan’s Health System (2017) (0)
0051: Cost-Effectiveness Analysis of Treatment Paradigms for Stage I and II Endometrial Cancer (2006) (0)
Vaccination in Vietnam Exploring Model Uncertainty in Economic Evaluation of Health Interventions : The Example of Rotavirus (2010) (0)
agree that further investigation of HCV infection-related qual- ity of life is a priority. (2017) (0)
A Model of HIV Patient Care: Methods and Applications to the Cost-Effectiveness of Anti-Viral Therapy (2000) (0)
A simulation-based comparative effectiveness analysis of policies to improve global maternal health outcomes. (2023) (0)
ARness of Human Papillomavirus DNA Testing in the United Kingdom, The Netherlands, France, and Italy (2005) (0)
PIN18 PROJECTED CLINICAL BENEFITS AND COSTEFFECTIVENESS OF AN HPV 16/18 VACCINE (2003) (0)
MC7 THE PHARMACOGENOMICS BIAS IN DECISION MODELS (2005) (0)
' s report Title : Factors influencing uptake and adherence of the quadrivalent human papillomavirus vaccine in an Ontario cohort of Grade 8 girls Version : 1 Date : 26 April 2011 (0)
O361 Cost‐effectiveness of alternative strategies for first‐trimester abortion in Mexico and Nigeria (2009) (0)
Comparative Evaluation of the Health and Economic Impact of Rotavirus versus HPV Vaccination in GAVI-Eligible Countries (2010) (0)
The Economic Burden of Noncervical Human Papillomavirus Disease in the United States (2008) (0)
Living-Donor Liver Transplantation for Chronic Hepatic Graft-versus-Host Disease (2006) (0)
Table 29.1, Number of Cancer Deaths and DALYs Lost to Cancer, by World Bank Region and Country Income Level, 2001 (2006) (0)
HPV Genotypes in Women with HIV (2006) (0)
PID6: HIV/AIDS HEALTH STATE UTILITIES USING COMMUNITY AND PATIENT PREFERENCE WEIGHTS: WHEN DOES IT MATTER? (2001) (0)

This paper list is powered by the following services:

Other Resources About Sue Goldie

en.wikipedia.org

What Schools Are Affiliated With Sue Goldie?

Sue Goldie is affiliated with the following schools:

Sue Goldie's Academic­Influence.com Rankings

Sue Goldie's Degrees

Why Is Sue Goldie Influential?

Sue Goldie's Published Works

Published Works

Other Resources About Sue Goldie

What Schools Are Affiliated With Sue Goldie?

Sue Goldie's AcademicInfluence.com Rankings